Hjem › Ikke-småcellet lungekreft › Pennsylvania › Lancaster
Kliniske studier for Ikke-småcellet lungekreft i Lancaster, PA
7 studier for Ikke-småcellet lungekreft søker deltakere på steder i og rundt Lancaster (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
RekruttererFase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134), Lancaster
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
RekruttererFase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0111), Lancaster
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
RekruttererFase 3
- Lancaster General Hospital, Lancaster
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0068), Lancaster
Pan-tumor MRD Study
RekruttererObservasjonsstudie
- Lancaster General Hospital (UPenn), Lancaster
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
RekruttererFase 3
- Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RekruttererFase 3
- Research Site, Lancaster
Ikke-småcellet lungekreft-studier i andre byer
- Houston, TX145 studier
- New York City, NY121 studier
- Arlington, VA104 studier
- Nashville, TN97 studier
- Boston, MA90 studier
- Los Angeles, CA87 studier
- St. Louis, MO73 studier
- Chicago, IL61 studier
- Baltimore, MD60 studier
- San Antonio, TX59 studier
- Columbus, OH57 studier
- Washington, DC55 studier
Andre studier i Lancaster
- Kardiovaskulær sykdom5 studier
- Hjertesvikt5 studier
- Brystkreft4 studier
- Prostatakreft4 studier
- Metastatisk kreft4 studier
- Lungekreft3 studier
- Amblyopi3 studier
- Hjertesykdommer3 studier
- Blærekreft3 studier
- Ikke-muskulinvasiv blærecancer3 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.